What’s the current market cap for Takeda Pharmaceutical stock?

Takeda Pharmaceutical (TAK) has a market cap of $49bn as of June 10, 2026.

What is the P/E ratio for Takeda Pharmaceutical stock?

The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 21.09 as of June 10, 2026.

Does Takeda Pharmaceutical stock pay dividends?

Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of June 10, 2026, the dividend rate is $0.52765 and the yield is 3.2%. Takeda Pharmaceutical has a payout ratio of 162.65% on a trailing twelve-month basis.

When is the next Takeda Pharmaceutical dividend payment date?

The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.

What is the beta indicator for Takeda Pharmaceutical?

Takeda Pharmaceutical (TAK) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Takeda Pharmaceutical stock | $TAK Share Price

About Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

Ticker

$TAK

Sector

Health

Primary listing

NYSE

Employees

47,455

Headquarters

Tokyo, Japan

Website

www.takeda.com

TAK Metrics

BasicAdvanced

$49bn

21.09

$0.75

0.09

$0.53

3.20%

What the Analysts think about TAK

Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.

Bulls say / Bears say

Takeda’s immunoglobulin drug candidate TAK-881 achieved the primary endpoint in a key Phase 2/3 trial for primary immunodeficiency disease, supporting regulatory filings in the U.S., EU, and Japan for FY2026 and expanding its revenue beyond existing products (Reuters)

A company-wide transformation program that includes AI adoption and process simplification is expected to yield more than ¥200 billion in annual gross savings by FY2028—including ¥100 billion in FY2026—improving margins and providing funds for strategic growth (Bloomberg)

The U.S. FDA accepted Takeda’s NDA for rusfertide and granted Priority Review, which puts the first-in-class polycythemia vera therapy on track for a potential late-2026 launch—addressing significant unmet need (Reuters)

Takeda expects to record restructuring charges of about ¥170 billion in FY2026, which will negatively impact near-term operating profit and cash flow as it absorbs one-time costs from its transformation program (Reuters)

The plan to cut around 4,500 jobs—about 9% of Takeda’s global workforce—as part of cost-cutting efforts could disrupt ongoing operations and risk the loss of important talent at a time when several product launches are upcoming (Reuters)

A $885 million pay-for-delay verdict in the Amitiza litigation highlights continuing legal liabilities for Takeda, which may erode cash reserves and distract management from strategic objectives (Bloomberg Law)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

TAK Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

TAK News

AllArticlesVideos

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

Business Wire·11 hours ago

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

Business Wire·3 weeks ago

Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds

Reuters·3 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.